<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813917</url>
  </required_header>
  <id_info>
    <org_study_id>08-005359</org_study_id>
    <secondary_id>CA132621-01A1</secondary_id>
    <nct_id>NCT00813917</nct_id>
  </id_info>
  <brief_title>Varenicline for the Treatment of Smokeless Tobacco</brief_title>
  <acronym>CHANCHEW</acronym>
  <official_title>Varenicline for the Treatment of Smokeless Tobacco Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with
      specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable
      efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel
      mechanism of action of varenicline potentially circumvents the limitations of using nicotine
      replacement therapy or bupropion pharmacotherapy in ST users. The overall goal of this line
      of research is to develop effective pharmacologic treatments for ST users to increase
      long-term (≥ 6 months) abstinence rates. The central hypothesis of this application is that
      varenicline is efficacious for the treatment of ST users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the United States, approximately 7.7 million individuals older than 12 years of age report
      current (past month) use of smokeless tobacco (ST). ST use has been associated with oral and
      extra-oral cancer as well as cardiovascular and cerebrovascular disease. To date, no
      pharmacotherapies have been shown to increase long-term (≥ 6 months) abstinence rates in ST
      users. Novel pharmacotherapies that decrease withdrawal symptoms and nicotine
      self-administration need to be tested in ST users. Varenicline (Chantix™, Pfizer) is a novel
      selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine
      acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term
      tobacco abstinence rates in cigarette smokers. The novel mechanism of action of varenicline
      potentially circumvents the limitations of using nicotine replacement therapy or bupropion
      pharmacotherapy in ST users. The overall goal of this line of research is to develop
      effective pharmacologic treatments for ST users to increase long-term (≥ 6 months) abstinence
      rates. The central hypothesis of this application is that varenicline is efficacious for the
      treatment of ST users. To evaluate this hypothesis, we will conduct a pilot study to obtain
      preliminary estimates of efficacy of 12-weeks of varenicline for increasing the prolonged and
      point prevalence tobacco abstinence rates at 12 weeks (end-of-treatment) in ST users. We will
      also evaluate the effect of varenicline on nicotine withdrawal symptoms and tobacco craving.
      If the results are promising, we will plan for a multicenter, randomized, double-blinded,
      placebo-controlled clinical trial with the Oregon Research Institute in Eugene, OR, to
      investigate the efficacy of varenicline to increase long-term (≥ 6 months) abstinence rates
      in ST users.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence All Tobacco Abstinence</measure>
    <time_frame>12 weeks - end of treatment</time_frame>
    <description>7-day point prevalence all tobacco abstinence at week 12 (end of treatment)confirmed by urine cotinine less than 50ng/ml</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>12 weeks of varenicline 1 mg by mouth twice per day</description>
    <arm_group_label>varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>12 weeks of placebo (double blinded) by mouth twice per day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Chantix placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible to participate if they:

          1. Are at least 18 years of age

          2. Have used ST daily for the past 12 months (regular user)

          3. Identify ST as their primary tobacco product

          4. Are in general good health (determined by medical history and screening physical
             examination)

          5. Has provided written informed consent to participate

          6. Are able to participate in all aspects of the study

        Exclusion Criteria:

        Individuals will be excluded from study participation if they:

          1. Are currently (in previous 30 days) using other behavioral or pharmacologic tobacco
             cessation programs (i.e., behavioral therapy, nicotine replacement therapy, clonidine,
             bupropion SR, or doxepin)

          2. Have self-reported current, untreated depression or a Beck Depression Inventory
             (BDI-II) Score of ≥ 20

          3. Have, as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale);current
             non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt
             (defined as &quot;potentially self-injurious act committed with at least some wish to die,
             as a result of act.&quot;)

          4. History of psychosis or bipolar disorder

          5. Are currently pregnant or lactating or is of childbearing potential and not willing to
             use any form of contraception

          6. Have another member of their household already participating in this study

          7. Are allergic to varenicline

          8. Describe having a medical history of:

               -  Unstable angina

               -  Myocardial infarction within the past 3 months

               -  Cardiac dysrhythmia other than medication-controlled atrial fibrillation or PSVT

               -  Medically-treated or untreated hypertension with BP ≥ 200 systolic OR ≥ 100
                  diastolic

               -  Have other medical or psychiatric conditions that would exclude the participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon O. Ebbert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nicotine Research Program</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. Nicotine Tob Res. 2011 Sep;13(9):820-6. doi: 10.1093/ntr/ntr078. Epub 2011 Apr 18.</citation>
    <PMID>21504885</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <results_first_submitted>August 5, 2011</results_first_submitted>
  <results_first_submitted_qc>September 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2011</results_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jon Ebbert</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
    <mesh_term>Lobeline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began on 4/13/09 and completed on 08/16/10. Interested subjects who passed a phone pre-screen were seen at a medical clinic (Mayo Clinic in Rochester, MN and Franciscan Skemp Medical Center in Lacrosse, WI) for consenting and additional study procedures to determine eligibility.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>varenicline-1mg/day for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>nonactive lookalike pill per day for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>varenicline-1mg/day for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>nonactive lookalike pill per day for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="12.4"/>
                    <measurement group_id="B2" value="40.7" spread="10.1"/>
                    <measurement group_id="B3" value="40.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smokeless tobacco quantity</title>
          <description>Amount of smokeless tobacco used per week</description>
          <units>cans per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="3.5"/>
                    <measurement group_id="B2" value="3.2" spread="2.0"/>
                    <measurement group_id="B3" value="3.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence All Tobacco Abstinence</title>
        <description>7-day point prevalence all tobacco abstinence at week 12 (end of treatment)confirmed by urine cotinine less than 50ng/ml</description>
        <time_frame>12 weeks - end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>varenicline-1mg/day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nonactive lookalike pill per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence All Tobacco Abstinence</title>
          <description>7-day point prevalence all tobacco abstinence at week 12 (end of treatment)confirmed by urine cotinine less than 50ng/ml</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data were compared between treatment groups using Chi Square test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.126</p_value>
            <p_value_desc>For this randomized phase II we used a one sided test with a false positive(type I error)rate of 0.20 to assess whether additional studies of the experimental arm are warranted.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>1 sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>varenicline-1mg/day for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>nonactive lookalike pill per day for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>hives</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>mood disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jon O. Ebbert, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-1944</phone>
      <email>nicotineresearch@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

